BIOCARDIA BCDA 深 沪
已收盘 08-01 16:00:00 美东时间
2.13
-0.010
-0.47%
华盛通- 最 高2.13
- 今 开2.13
- 成交量 1.52万股
- 最 低 2.0551
- 昨 收 2.14
- 总市值 1102.89万
- 52周最高 4.66
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.625
- 委 比 92.31%
- 总股本 517.79万
- 历史最高 129.00
- 量 比 0.56
- 振 幅 3.50%
- 历史最低 1.7272
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCardia Submits CardiAMP Autologous Cell Therapy Investigational Heart Failure Treatment For Clinical Consultation With Japan's Pharmaceuticals And Medical Devices Agency
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAMP autologous cell
07-24 21:08
BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure
<p><p align="left">BioCardia, Inc. announced the submission of its investigational heart failure treatment, the CardiAMP autologous cell therapy, for clinical consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This submission includes detailed clinical data, completing the regulatory pathway for potential approval in Japan. The PMDA will review the efficacy, safety, and appropriate use of CardiAMP in heart failure patien...
07-24 13:00
港股芯片股拉升，华虹半导体涨超5%
7月24日消息，港股芯片股拉升，ASMPT涨超8%，华虹半导体涨超5%，中芯国际、上海复旦涨超3%。 7月17日，台积电公布2025年第二季度财务...
07-24 10:21
资金动向 | 北水连续2日加仓中国人寿，抛售腾讯超11亿港元
7月23日，南下资金净卖出港股13.2亿港元。 其中，净买入中国人寿6.65亿、中芯国际4.86亿、中国能源建设2.56亿、阿里巴巴-W 2.02亿、泡泡玛特...
07-23 20:07
资金动向 | 北水猛加仓雅下水电概念！连续4日净买入中芯国际
7月22日，南下资金净买入港股27.17亿港元。 其中，净买入中国人寿8.78亿、建设银行7.55亿、中芯国际5.11亿、美团-W 3.82亿、华新水泥3.3...
07-22 19:11
BioCardia Launches Phase 3 CardiAMP HF II Trial
BioCardia ( ($BCDA) ) has provided an update. On July 16, 2025, BioCardia annou...
07-16 21:15
Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
BioCardia, Inc. announced that Henry Ford Health in Detroit is enrolling patients with ischemic HFrEF in the CardiAMP HF II trial, a pivotal study for autologous bone marrow-derived mononuclear cell therapy. The trial aims to confirm the safety and efficacy of this therapy, which promotes microvascular repair and improves heart function. CardiAMP HF II is a 250-patient, randomized, multicenter, placebo-controlled study targeting patients on guide...
07-16 12:45
BioCardia Completes Private Placement Agreement
BioCardia ( ($BCDA) ) has issued an announcement. On June 30, 2025, BioCardia, ...
07-03 00:58
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System
BioCardia®, Inc. announced the U.S. Patent Office granted US Patent No. 12,311,127 for its "Radial and Trans-endocardial Delivery Catheter," a minimally invasive system for delivering biologics to the heart. The patent protects their helical needle-tipped catheter technology, which studies show is the safest and most efficient for biotherapeutic delivery. CEO Dr. Peter Altman highlighted the technology's role in the CardiAMP Cell Therapy program,...
06-25 12:00
BioCardia shares are trading lower after the company reported worse-than-expected Q1 EPS results.
BioCardia shares are trading lower after the company reported worse-than-expect...
05-16 01:04
